• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans.

作者信息

Lesko L J, Rowland M, Peck C C, Blaschke T F, Breimer D, de Jong H J, Grahnen A, Kuhlmann J J, Stewart B

机构信息

Office of Clinical Pharmacology and Biopharmaceutics, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD 20851, USA.

出版信息

Eur J Pharm Sci. 2000;10(4):iv-xiv. doi: 10.1016/s0928-0987(00)00092-0.

DOI:10.1016/s0928-0987(00)00092-0
PMID:11023342
Abstract
摘要

相似文献

1
Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans.优化药物研发科学：改善候选药物选择及加速人体评估的机遇。
Eur J Pharm Sci. 2000;10(4):iv-xiv. doi: 10.1016/s0928-0987(00)00092-0.
2
Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans.优化药物研发科学：改善候选药物选择及加速人体评估的机遇
Pharm Res. 2000 Nov;17(11):1335-44. doi: 10.1023/a:1007574217260.
3
Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans.优化药物研发科学：改善候选药物选择及加速人体评估的机遇。
J Clin Pharmacol. 2000 Aug;40(8):803-14. doi: 10.1177/00912700022009530.
4
An integrated early formulation strategy--from hit evaluation to preclinical candidate profiling.一种综合的早期制剂策略——从活性分子评估到临床前候选药物剖析。
Eur J Pharm Biopharm. 2007 Apr;66(1):1-10. doi: 10.1016/j.ejpb.2006.09.011. Epub 2006 Oct 6.
5
Strategies for success in drug development.药物研发成功的策略。
Retina. 2005 Dec;25(8 Suppl):S100-S102. doi: 10.1097/00006982-200512001-00051.
6
Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities.通过定量转化和临床药理学优化肿瘤治疗：挑战与机遇
Clin Pharmacol Ther. 2015 Jan;97(1):37-54. doi: 10.1002/cpt.7. Epub 2014 Dec 9.
7
Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.口服生物药剂学工具——开启新计划的时机——IMI项目OrBiTo介绍
Eur J Pharm Sci. 2014 Jun 16;57:292-9. doi: 10.1016/j.ejps.2013.10.012. Epub 2013 Nov 1.
8
Introduction of quantitative methods in pharmacology and clinical pharmacology: a historical overview.药理学与临床药理学中定量方法的引入：历史概述
Clin Pharmacol Ther. 2007 Jul;82(1):3-6. doi: 10.1038/sj.clpt.6100248.
9
The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies.临床试验中选择单克隆抗体首次人体剂量的最低预期生物学效应水平（MABEL）。
Curr Opin Biotechnol. 2009 Dec;20(6):722-9. doi: 10.1016/j.copbio.2009.10.013. Epub 2009 Nov 5.
10
The return of the prodigal son and the extraordinary development route of antibody TGN1412 - lessons for drug development and clinical pharmacology.浪子回头与抗体TGN1412的非凡发展历程——药物研发与临床药理学的教训
Br J Clin Pharmacol. 2015 Apr;79(4):545-7. doi: 10.1111/bcp.12605.

引用本文的文献

1
Absolute Bioavailability, Tissue Distribution, and Excretion of Erinacine S in Mycelia.蛇菰素 S 在菌丝体中的绝对生物利用度、组织分布和排泄。
Molecules. 2019 Apr 24;24(8):1624. doi: 10.3390/molecules24081624.
2
Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.杜氏肌营养不良症的药物治疗：靶点识别与临床前试验
ILAR J. 2014;55(1):119-49. doi: 10.1093/ilar/ilu011.
3
Getting the Dose Right: report from the Tenth European Federation of Pharmaceutical Sciences (EUFEPS) conference on optimizing drug development.
精准给药：第十届欧洲药物科学联合会（EUFEPS）优化药物研发会议报告
J Pharmacokinet Pharmacodyn. 2005 Apr;32(2):199-211. doi: 10.1007/s10928-005-0010-x. Epub 2005 Nov 7.
4
Uncertainty analysis in pharmacokinetics and pharmacodynamics: application to naratriptan.药代动力学和药效学中的不确定性分析：应用于那拉曲普坦
Pharm Res. 2005 Oct;22(10):1614-26. doi: 10.1007/s11095-005-6629-x. Epub 2005 Sep 22.
5
Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development.正电子发射断层扫描微剂量给药：一种应用于示踪剂和早期临床药物开发的新概念。
Eur J Clin Pharmacol. 2003 Sep;59(5-6):357-66. doi: 10.1007/s00228-003-0643-x. Epub 2003 Aug 22.
6
Utilisation of pharmacokinetic-pharmacodynamic modelling and simulation in regulatory decision-making.药代动力学-药效学建模与模拟在监管决策中的应用。
Clin Pharmacokinet. 2001;40(12):883-92. doi: 10.2165/00003088-200140120-00001.
7
Modeling and stimulation for clinical trial design involving a categorical response: a phase II case study with naratriptan.涉及分类反应的临床试验设计的建模与模拟：那拉曲坦的II期案例研究
Pharm Res. 2001 Aug;18(8):1210-9. doi: 10.1023/a:1010943430471.
8
Concentration-controlled or effect-controlled trials: useful alternatives to conventional dose-controlled trials?浓度控制或效应控制试验：传统剂量控制试验的有用替代方法？
Clin Pharmacokinet. 2001;40(5):317-25. doi: 10.2165/00003088-200140050-00001.